Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06149832
Other study ID # cGVHD001
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date November 30, 2023
Est. completion date November 30, 2023

Study information

Verified date November 2023
Source Southwest Hospital, China
Contact Lei Gao
Phone 13228689635
Email gaolei7765@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic graft-versus-host disease (cGVHD) is a clinicopathological syndrome caused by donor lymphocytes attacking the recipient's organs during the process of reestablishing donor immunity after allogeneic hematopoietic stem cell transplantation (allo-HSCT), with an incidence of about 30%-70%. The clinical manifestations of cGVHD are varied, the course of the disease is prolonged, and the quality of life of patients is affected, and the long-term survival is affected. Among them, oral cGVHD is the most common type, which mainly presents with lichen planus, oral ulcers, mucosal atrophy, erythema and pain. At present, the treatment of oral cGVHD is based on systemic treatment and local hormone-containing gargling solution and local photochemotherapy. The former is easy to be complicated by oral local fungal infection, while the latter has no such equipment in China. Therefore, it is urgent to establish a simple, effective and low-toxicity local treatment for oral cGVHD. Mesenchymal stem cells (MSCs) are one of the most widely used cell products in clinic. The combination of MSCS and hematopoietic stem cells can improve the success rate of transplantation and accelerate hematopoietic reconstruction. The applicant team previously completed a national multi-center clinical study on MSCs prevention of cGVHD, which proved that sequential infusion of MSCs can effectively reduce the incidence of cGVHD, and the mechanism is that MSCs regulate Th1: Th2 balance and promote the differentiation of T cells to Th1 direction. Our previous mechanism study provides an important theoretical basis for MSCs treatment of oral cGVHD. According to the clinical needs and the rich experience of our research group in the field of MSCs clinical research, we plan to use dressing containing MSCs for the local treatment of oral cGVHD, so as to improve the lesion degree of oral cGVHD and improve the quality of life of allo-HSCT patients, and provide clinical experience for reference for the local treatment of MSCs graft-versus-host disease.


Recruitment information / eligibility

Status Recruiting
Enrollment 38
Est. completion date November 30, 2023
Est. primary completion date November 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. No gender limitation, age <65 years old; KPS score >60, estimated survival >3 months. 2. No serious damage to the function of major organs of the whole body. 3. Donor hematopoietic reconstruction was stable (neutrophils >0.5×10^9/L, platelets >20×10^9/L). 4. Stable control of primary blood diseases. 5. Voluntary examination, informed consent. Exclusion Criteria: 1. Have severe heart, kidney or liver dysfunction. 2. Those combined with other malignant tumors need treatment. 3. There are clinical symptoms of brain dysfunction or severe mental illness and the inability to understand or follow the research protocot4. Patients who cannot be guaranteed to complete the necessary treatment plan and follow-up observation. 5. Patients with severe acute allergic reactions. 6. Clinically uncontrolled active infection. 7. Patients who are participating in other clinical trials. 8. Researchers believe that the subject is not suitable for clinical trials for other reasons.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Mesenchymal Stem Cells (MSCs)
The patient's mouth (including buccal mucosa, tongue and lip) was applied with MSCs: MSCs (1×10^6/ml) dressing was applied 4 times/day for 2 weeks.

Locations

Country Name City State
China Xinqiao Hospital Shapingba Chongqing

Sponsors (2)

Lead Sponsor Collaborator
Southwest Hospital, China Xinqiao Hospital of Chongqing

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Oral cGVHD improves condition Oral cGVHD score after 2 weeks of treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01221428 - Umbilical Cord Mesenchymal Stem Cells Infusion for Ulcerative Colitis Phase 1/Phase 2
Active, not recruiting NCT01219465 - Umbilical Cord Mesenchymal Stem Cells Infusion for Initial Type 1 Diabetes Mellitus Phase 1/Phase 2
Completed NCT03105284 - Adipose-tissue Derived Stem Cells in Flaps Versus Liposuction N/A
Not yet recruiting NCT01224327 - Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients Phase 1/Phase 2
Recruiting NCT05165459 - Open Label Single Arm Proof of Concept Trial to Evaluate the Efficacy and Safety of Cytori Celution System in Chronic Non-Healing Venous Leg Ulcers N/A
Active, not recruiting NCT04014166 - Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia N/A
Not yet recruiting NCT06077734 - Muscle Stem Cell Quality in Atrophy
Completed NCT00956891 - Therapeutic Effects of Liver Failure Patients Caused by Chronic Hepatitis B After Autologous MSCs Transplantation Phase 1/Phase 2
Recruiting NCT01218464 - Safety and Efficacy of Human Mesenchymal Stem Cells for Treatment of Liver Failure Phase 1/Phase 2
Active, not recruiting NCT03874572 - Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth Phase 1
Recruiting NCT00953485 - Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS) Phase 1/Phase 2
Not yet recruiting NCT04863183 - Cell Therapy With Cellistem-OA for Symptomatic Knee Osteoarthritis Phase 1/Phase 2
Completed NCT06360861 - Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1
Completed NCT05018754 - Treatment of Oral Mucositis Using Platelet Rich Fibrin TREATMENT OF ORAL MUCOSITIS USING PRF
Recruiting NCT04356287 - Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis Phase 1/Phase 2
Completed NCT03130374 - Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells Phase 1/Phase 2
Active, not recruiting NCT02673788 - Follow-Up Study of Safety of Pneumostem® in Premature Infants With Intraventricular Hemorrhage
Recruiting NCT01763086 - Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant Phase 2
Recruiting NCT01763099 - Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure Phase 2
Completed NCT02302599 - Mesenchymal Stem Cells to Treat Type 2 Diabetes Phase 2